Background and objective In patients with severe interstitial lung disease (ILD) progressing
despite conventional immunosuppression, rituximab, a B‐lymphocyte depleting monoclonal …

Background: Interstitial lung disease (ILD) is a common pulmonary disease often associated
with significant morbidity and mortality in patients with connective tissue diseases (CTD) …

It is found that despite differences in clinical presentation and response to treatment,
similarities are noted in proposed pathogenesis and putative biomarkers. It is hoped that this …

Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary
fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of …

With improvements in the systemic treatment of the various connective tissue diseases
(CTDs) the pulmonary complications of these conditions are now, for many patients, the …

Interstitial lung disease (ILD) refers to a large and heterogeneous group of parenchymal
lung disorders [1], some related to other diseases such as connective tissue diseases …

Background In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases
(ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with …

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc) and
mainly encountered in patients with diffuse disease and/or anti-topoisomerase 1 antibodies …

Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA)
contributing to significantly increased morbidity and mortality. Other respiratory …

Background Interstitial lung disease-associated antisynthetase syndrome (AS-ILD) carries
significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are the …